ClinicalTrials.gg
Active, not recruitingNCT04906993Updated Sep 9, 2025

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

A Phase 3 interventional study of camrelizumab; famitinib malate and platinum-based chemotherapy in Cervical Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
69th of 360
443 · median 90
Started
2021
with 51 others
Phase 3
56 of 455
21 open now
Primary completion
2025-06
later than 61 of 239 live
Registered
176th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 69th largest by enrollment of the 360 interventional ones that give a count, is one of 52 that started in 2021, is one of 56 in phase 3, reaches primary completion later than 61 of the 239 other live ones, and was the 176th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female aged 18-75 years (including 18 and 75 years, calculated based on the signing date of the )
  2. Histopathologically confirmed recurrent/ cervical squamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy
  3. No prior systemic anti-cancer therapy for recurrent/metastatic disease
  4. According to v1.1 criteria, the patient must have at least one
  5. Able to normally swallow drug tablets
  6. The organ function level is good
  7. Willing to participate and able to comply with research programme requirements

Exclusion criteria

Exclusion Criteria:

  1. Has any \<5 years prior to study entry.
  2. Known to have brain or meningeal
  3. Known to have disease
  4. Received 4 weeks before randomization or during the study period
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    camrelizumab combined with famitinib malate

    Drug: camrelizumab; famitinib malate

  • Active comparator
    platinum-based chemotherapy

    Drug: platinum-based chemotherapy

Interventions

  • Drugcamrelizumab; famitinib malate

    Camrelizumab intravenously ; Famitinib Orally

  • Drugplatinum-based chemotherapy

    Physician's choice chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by the BIRC based on RECIST V1.1 criteria

    Time frame: up to 2 years

  2. Overall survival (OS)

    Time frame: up to 3 years

Secondary outcomes

  1. Progression-free survival (PFS) assessed by the investigator based on RECIST V1.1 criteria

    Time frame: up to 2 years

  2. Objective response rate (ORR) assessed based on RECIST V1.1 criteria

    Time frame: up to 2 years

  3. Disease control rate (DCR) assessed based on RECIST V1.1 criteria

    Time frame: up to 2 years

  4. Duration of response (DOR) assessed based on RECIST V1.1 criteria

    Time frame: up to 2 years

  5. Time to response (TTR) assessed based on RECIST V1.1 criteria

    Time frame: up to 2 years

  6. Time to treatment failure (TTF)

    Time frame: up to 2 years

  7. Progression-free survival (PFS) in subjects in the control group who receive camrelizumab after progression

    Time frame: up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2025, 46 months.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 46 months is above that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2021
First posted
May 28, 2021
StartActual
Jul 23, 2021
Primary completionActual
Jun 10, 2025
CompletionEst.
May 31, 2027
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04906993
Responsible party
Sponsor
First posted
May 28, 2021
Start date
Jul 23, 2021
Primary completion
Jun 10, 2025
Completion
May 31, 2027 (estimated)
Last update
Sep 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion